CN109803534A - 用于治疗炎性肠病（ibd）和其他疾病的组合物和方法 - Google Patents

用于治疗炎性肠病（ibd）和其他疾病的组合物和方法 Download PDF

Info

Publication number
CN109803534A
CN109803534A CN201780043664.8A CN201780043664A CN109803534A CN 109803534 A CN109803534 A CN 109803534A CN 201780043664 A CN201780043664 A CN 201780043664A CN 109803534 A CN109803534 A CN 109803534A
Authority
CN
China
Prior art keywords
kinds
pharmaceutical composition
microorganism
fecal
bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780043664.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·J·鲍罗迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finch Research and Development LLC
Original Assignee
Crestovo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crestovo LLC filed Critical Crestovo LLC
Publication of CN109803534A publication Critical patent/CN109803534A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201780043664.8A 2016-06-01 2017-06-01 用于治疗炎性肠病（ibd）和其他疾病的组合物和方法 Pending CN109803534A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344053P 2016-06-01 2016-06-01
US62/344,053 2016-06-01
PCT/US2017/035449 WO2017210428A1 (en) 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders

Publications (1)

Publication Number Publication Date
CN109803534A true CN109803534A (zh) 2019-05-24

Family

ID=60479147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043664.8A Pending CN109803534A (zh) 2016-06-01 2017-06-01 用于治疗炎性肠病（ibd）和其他疾病的组合物和方法

Country Status (7)

Country Link
US (2) US20170348360A1 (enExample)
EP (1) EP3462882A4 (enExample)
JP (1) JP2019520340A (enExample)
CN (1) CN109803534A (enExample)
AU (1) AU2017274416C1 (enExample)
CA (1) CA3026414A1 (enExample)
WO (1) WO2017210428A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
CN111107860A (zh) * 2017-06-16 2020-05-05 表飞鸣制药株式会社 脂肪相关疾病和/或炎症的预防或治疗剂
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
CN113974159A (zh) * 2021-11-02 2022-01-28 美益添生物医药(武汉)有限公司 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用
CN115279383A (zh) * 2019-12-17 2022-11-01 埃克塞利翁生物科学公司 用于治疗和预防胃肠炎症的普拉梭菌菌株cncm i-4573与pentasa®的组合
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
CN115697084A (zh) * 2020-04-01 2023-02-03 沃尔夫森医疗中心 溃疡性结肠炎膳食、配方、产品及其方法
CN119970806A (zh) * 2025-02-25 2025-05-13 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3297644T (pt) 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
US20200268017A1 (en) * 2017-06-20 2020-08-27 Cornell University Probiotic compositions and methods
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
WO2019113096A1 (en) 2017-12-05 2019-06-13 BioPlx, Inc. Methods and compositions to prevent microbial infection
WO2019117212A1 (ja) * 2017-12-12 2019-06-20 森永乳業株式会社 ビフィドバクテリウム属細菌を有効成分とする組成物
TWI813620B (zh) 2018-02-02 2023-09-01 香港中文大學 糞便微生物群移植的糞便真菌微生物和治療功效
WO2019157566A1 (en) * 2018-02-16 2019-08-22 St Vincent's Hospital (Melbourne) Limited Compositions and methods for promoting gut health
EP3773647A4 (en) * 2018-04-13 2022-01-26 Med-Life Discoveries LP LONG CHAIN DICARBOXYLIC FATTY ACID (LCDFA) PRODUCING MICROBES AND THEIR USES
CN110396538B (zh) * 2018-04-24 2023-05-23 深圳华大生命科学研究院 偏头痛生物标志物及其用途
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US12144834B2 (en) * 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US20220218761A1 (en) * 2019-05-06 2022-07-14 The General Hospital Corporation Monitoring and altering the gut microbiome in disease
CN114364388A (zh) * 2019-07-11 2022-04-15 安东尼·米利斯 一种增强微生物植入的肠黏膜制备方法
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
EP4045069A1 (en) * 2019-10-18 2022-08-24 Thaena Inc. Fecal-derived sterile postbiotic composition and method therefor
EP3839072A1 (en) * 2019-12-17 2021-06-23 Luxia Scientific Bacterial combinations predictive of the activity of multiple sclerosis
US20230087012A1 (en) * 2020-02-14 2023-03-23 Cornell University Transferable microbiota for the treatment of ulcerative colitis
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
EP3875098A1 (en) * 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US20230256033A1 (en) * 2020-06-09 2023-08-17 Flagship Pioneering Innovations Vi, Llc Physiologically acceptable compositions containing microorganisms or microbial products
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
EP4188110A4 (en) * 2020-07-30 2024-08-14 Bactana Corp. METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES
JP7570506B2 (ja) * 2020-09-28 2024-10-21 シージェイ バイオサイエンス， インク． 微生物を含む炎症性疾患の診断または治療用組成物
WO2022212510A1 (en) * 2021-04-01 2022-10-06 Medibeacon Inc. Methods of monitoring mucosal healing
EP4082545A1 (en) * 2021-04-27 2022-11-02 Diotheris Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023219175A1 (ja) * 2022-05-13 2023-11-16 国立大学法人 東京大学 炎症性腸疾患（ｉｂｄ）を治療または診断する方法および組成物
CN115944655A (zh) * 2023-02-14 2023-04-11 上海奇诺普森生物科技有限责任公司 一种肠菌组合物及其在防治自闭症中的应用
CN119709558B (zh) * 2025-02-26 2025-05-30 昆明医科大学第一附属医院(云南省皮肤病医院) 布劳特氏菌emf75-02b1b及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275848A1 (en) * 2003-08-27 2006-12-07 Universiteit Utrecht Holding B. V. Diagnosis and treatment of microbacterial infections
CN103124559A (zh) * 2010-08-04 2013-05-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
CN103561752A (zh) * 2011-03-09 2014-02-05 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US20140328803A1 (en) * 2013-02-04 2014-11-06 Seres Health, Inc. Compositions and Methods
US20140363397A1 (en) * 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
US20150283144A1 (en) * 2012-11-01 2015-10-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
CN105228635A (zh) * 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F（DSM 26943）在抑制炎症中的应用
US20160143961A1 (en) * 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783858B2 (en) * 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275848A1 (en) * 2003-08-27 2006-12-07 Universiteit Utrecht Holding B. V. Diagnosis and treatment of microbacterial infections
CN103124559A (zh) * 2010-08-04 2013-05-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
CN103561752A (zh) * 2011-03-09 2014-02-05 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US20140363397A1 (en) * 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20150283144A1 (en) * 2012-11-01 2015-10-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
US20140328803A1 (en) * 2013-02-04 2014-11-06 Seres Health, Inc. Compositions and Methods
US9180147B2 (en) * 2013-02-04 2015-11-10 Seres Therapeutics, Inc. Compositions and methods
CN105228635A (zh) * 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F（DSM 26943）在抑制炎症中的应用
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
US20160143961A1 (en) * 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EMMA ALLEN-VERCOE: ""Fusobacterium varium in Ulcerative Colitis: Is It Population-Based?"", 《DIGESTIVE DISEASE AND SCIENCES》 *
HARRY SOKOL 等: ""Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients"", 《PNAS》 *
KAREN P. SCOTT 等: ""Manipulating the gut microbiota to maintain health and treat disease"", 《MICROBIAL ECOLOGY IN HEALTH AND DISEASE》 *
MARIO MATIJAŠIC 等: ""Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients"", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 *
MIREIA LOPEZ-SILES 等: ""Cultured Representatives of Two Major Phylogroups of Human Colonic Faecalibacterium prausnitzii Can Utilize Pectin, Uronic Acids, and Host-Derived Substrates for Growth"", 《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》 *
ORIANA ROSSI 等: ""Faecalibacterium prausnitzii Strain HTF-F and Its Extracellular Polymeric Matrix Attenuate Clinical Parameters in DSS-Induced Colitis"", 《PLOS ONE》 *
ZI-KAI WANG 等: ""Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease"", 《WORLD J GASTROENTEROL》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107860A (zh) * 2017-06-16 2020-05-05 表飞鸣制药株式会社 脂肪相关疾病和/或炎症的预防或治疗剂
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
CN115279383A (zh) * 2019-12-17 2022-11-01 埃克塞利翁生物科学公司 用于治疗和预防胃肠炎症的普拉梭菌菌株cncm i-4573与pentasa®的组合
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
CN115697084A (zh) * 2020-04-01 2023-02-03 沃尔夫森医疗中心 溃疡性结肠炎膳食、配方、产品及其方法
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
CN113974159A (zh) * 2021-11-02 2022-01-28 美益添生物医药(武汉)有限公司 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用
CN119970806A (zh) * 2025-02-25 2025-05-13 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用

Also Published As

Publication number Publication date
AU2017274416B2 (en) 2022-01-27
US20210106629A1 (en) 2021-04-15
US20170348360A1 (en) 2017-12-07
AU2017274416A1 (en) 2019-01-03
JP2019520340A (ja) 2019-07-18
WO2017210428A1 (en) 2017-12-07
EP3462882A4 (en) 2020-01-22
CA3026414A1 (en) 2017-12-07
EP3462882A1 (en) 2019-04-10
AU2017274416C1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
CN109803534A (zh) 用于治疗炎性肠病（ibd）和其他疾病的组合物和方法
JP7737219B2 (ja) 潰瘍性大腸炎を治療するための方法
JP6856968B2 (ja) 自閉症スペクトラム障害および関連する症候を治療するための方法
US20160129053A1 (en) Methods of isolating microorganisms and uses thereof
WO2017218681A1 (en) Methods for treating autism spectrum disorder and associated symptoms
CN109789172A (zh) 用于难辨梭菌治疗的组合物和方法
JP2022547330A (ja) 自閉症スペクトラム障害を治療するための組成物および方法
US11213549B2 (en) Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071534A1 (en) Compositions and methods for treating irritable bowel syndrome and related disorders
JP2020513018A (ja) パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
US20180099011A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
WO2018071537A1 (en) Compositions and methods for treating multiple sclerosis and related disorders
US20200188449A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
US20240173360A1 (en) Compositions and methods for treating epilepsy and related disorders
WO2021142358A1 (en) Compositions and methods for treating hepatic encephalopathy (he)
TW202140049A (zh) 用於治療ｂ型肝炎（ｈｂｖ）及ｄ型肝炎（ｈｄｖ）之組合物及方法
US20180099013A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
US11529375B2 (en) Compositions and methods for treating diverticulitis and related disorders
WO2021142347A1 (en) Compositions and methods for non-alcoholic steatohepatitis (nash)
HK40009325A (en) Methods for treating ulcerative colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190524